Skip to main content
. 2021 Mar 4;61(4):245–252. doi: 10.2176/nmc.oa.2020-0308

Table 3. Univariate and multivariate analyses of clinical factors for survival after cytoreductive surgery by the proportional hazard model.

Univariate analysis Multivariate analysis
Hazard ratio 95% CI P values Hazard ratio 95% CI P values
Age at recurrence (continuous variable) 1.001 0.97–1.03 0.96
Interval between surgeries (continuous variable) 0.993 0.97–1.01 0.47
Preoperative KPS <80% 1 1
80–100% 0.43 0.14–1.35 0.15 1.20 0.31–4.54 0.78
KPS change after surgery decrease 1 1
stable 0.24 0.09–0.66 0.005 0.22 0.07–0.71 0.01*
Extent of Resection (%) (continuous variable) 0.98 0.95–1.02 0.37
BCNU wafer implantation no 1 1
yes 0.48 0.19–1.17 0.11 1.12 0.37–3.46 0.84
BEV available after surgery yes 1 1
no 3.19 1.27–7.98 0.013 3.34 1.11–10.1 0.03*

BEV: bevacizumab, CI: confidence interval, KPS: Karnofsky Performance Status.